361 related articles for article (PubMed ID: 26747390)
21. [The Polypill - A Practicable Approach?].
Thürmann PA; Kleinerüschkamp AG; Boehme P
Dtsch Med Wochenschr; 2019 Jun; 144(11):715-718. PubMed ID: 31163467
[TBL] [Abstract][Full Text] [Related]
22. Pharmacodynamic study of the cardiovascular polypill. Is there any interaction among the monocomponents?
González-Juanatey JR; Tamargo J; Torres F; Weisser B; Oudovenko N
Rev Esp Cardiol (Engl Ed); 2021 Jan; 74(1):51-58. PubMed ID: 31983653
[TBL] [Abstract][Full Text] [Related]
23. The concept of the polypill in the prevention of cardiovascular disease.
Wiley B; Fuster V
Ann Glob Health; 2014; 80(1):24-34. PubMed ID: 24751562
[TBL] [Abstract][Full Text] [Related]
24. The CNIC-Polypill reduces recurrent major cardiovascular events in real-life secondary prevention patients in Spain: The NEPTUNO study.
González-Juanatey JR; Cordero A; Castellano JM; Masana L; Dalmau R; Ruiz E; Sicras-Mainar A; Fuster V
Int J Cardiol; 2022 Aug; 361():116-123. PubMed ID: 35569611
[TBL] [Abstract][Full Text] [Related]
25. Safety and efficacy of a cardiovascular polypill in people at high and very high risk without a previous cardiovascular event: the international VULCANO randomised clinical trial.
Mostaza JM; Suárez-Fernández C; Cosín-Sales J; Gómez-Huelgas R; Brotons C; Araujo FP; Borrayo G; Ruiz E;
BMC Cardiovasc Disord; 2022 Dec; 22(1):560. PubMed ID: 36550424
[TBL] [Abstract][Full Text] [Related]
26. The cardiovascular polypill: clinical data and ongoing studies.
Castellano JM; Bueno H; Fuster V
Int J Cardiol; 2015 Dec; 201 Suppl 1():S8-14. PubMed ID: 26747391
[TBL] [Abstract][Full Text] [Related]
27. Preservation of bioavailability of ingredients and lack of drug-drug interactions in a novel five-ingredient polypill (polycap): a five-arm phase I crossover trial in healthy volunteers.
Patel A; Shah T; Shah G; Jha V; Ghosh C; Desai J; Khamar B; Chakraborty BS
Am J Cardiovasc Drugs; 2010; 10(2):95-103. PubMed ID: 20334446
[TBL] [Abstract][Full Text] [Related]
28. A practical approach to switch from a multiple pill therapeutic strategy to a polypill-based strategy for cardiovascular prevention in patients with hypertension.
Coca A; Kreutz R; Manolis AJ; Mancia G
J Hypertens; 2020 Oct; 38(10):1890-1898. PubMed ID: 32890261
[TBL] [Abstract][Full Text] [Related]
29. The need to test the theories behind the Polypill: rationale behind the Indian Polycap Study.
Xavier D; Pais P; Sigamani A; Pogue J; Afzal R; Yusuf S;
Nat Clin Pract Cardiovasc Med; 2009 Feb; 6(2):96-7. PubMed ID: 19104516
[No Abstract] [Full Text] [Related]
30. Cost-effectiveness and public health benefit of secondary cardiovascular disease prevention from improved adherence using a polypill in the UK.
Becerra V; Gracia A; Desai K; Abogunrin S; Brand S; Chapman R; García Alonso F; Fuster V; Sanz G
BMJ Open; 2015 May; 5(5):e007111. PubMed ID: 25991449
[TBL] [Abstract][Full Text] [Related]
31. Real-life effect on the control of risk factors associated with initiation of the cardiovascular polypill created from equipotent drugs.
Portela-Romero M; Cinza-Sanjurjo S; Conde-Sabarís P; Rodríguez-Mañero M; Mazón-Ramos P; Rey-Aldana D; González-Juanateyc JR
Rev Clin Esp (Barc); 2022 Mar; 222(3):131-137. PubMed ID: 34674985
[TBL] [Abstract][Full Text] [Related]
32. PolyPill for Prevention of Cardiovascular Disease in an Urban Iranian Population with Special Focus on Nonalcoholic Steatohepatitis: A Pragmatic Randomized Controlled Trial within a Cohort (PolyIran - Liver) - Study Protocol.
Merat S; Poustchi H; Hemming K; Jafari E; Radmard AR; Nateghi A; Shiravi Khuzani A; Khoshnia M; Marshall T; Malekzadeh R
Arch Iran Med; 2015 Aug; 18(8):515-23. PubMed ID: 26265520
[TBL] [Abstract][Full Text] [Related]
33. Practical Decision Algorithms for the Use of the Cardiovascular Polypill in Secondary Prevention in Europe.
Grigorian-Shamagian L; Edel K; Esteve-Pastor MA; Aceña Á; Silva C; Delgado-Silva J; Ntaios G; Demerouti E; Brotons C
Front Cardiovasc Med; 2021; 8():663361. PubMed ID: 34504874
[TBL] [Abstract][Full Text] [Related]
34. Use of a Multidrug Pill In Reducing cardiovascular Events (UMPIRE): rationale and design of a randomised controlled trial of a cardiovascular preventive polypill-based strategy in India and Europe.
Thom S; Field J; Poulter N; Patel A; Prabhakaran D; Stanton A; Grobbee DE; Bots ML; Reddy KS; Cidambi R; Rodgers A
Eur J Prev Cardiol; 2014 Feb; 21(2):252-61. PubMed ID: 23038750
[TBL] [Abstract][Full Text] [Related]
35. The CNIC-polypill (acetylsalicylic acid, atorvastatin, and ramipril), an effective and cost-saving secondary prevention strategy compared with other therapeutic options in patients with ischaemic heart disease.
Dalmau R; Cordero A; Masana L; Ruiz E; Sicras-Mainar A; González-Juanatey JR
Eur Heart J Open; 2024 Mar; 4(2):oeae027. PubMed ID: 38686352
[TBL] [Abstract][Full Text] [Related]
36. Role of the polypill for secondary prevention in ischaemic heart disease.
Castellano JM; Fuster V; Jennings C; Prescott E; Bueno H
Eur J Prev Cardiol; 2017 Jun; 24(3_suppl):44-51. PubMed ID: 28618914
[TBL] [Abstract][Full Text] [Related]
37. The evening versus morning polypill utilization study: the TEMPUS rationale and design.
Lafeber M; Grobbee DE; Bots ML; Thom S; Webster R; Rodgers A; Visseren FL; Spiering W
Eur J Prev Cardiol; 2014 Apr; 21(4):425-33. PubMed ID: 23382539
[TBL] [Abstract][Full Text] [Related]
38. Polypill: lights and shadows.
Teo KK; Liang Y
Curr Hypertens Rep; 2010 Aug; 12(4):276-81. PubMed ID: 20549577
[TBL] [Abstract][Full Text] [Related]
39. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk.
Patel A; Cass A; Peiris D; Usherwood T; Brown A; Jan S; Neal B; Hillis GS; Rafter N; Tonkin A; Webster R; Billot L; Bompoint S; Burch C; Burke H; Hayman N; Molanus B; Reid CM; Shiel L; Togni S; Rodgers A;
Eur J Prev Cardiol; 2015 Jul; 22(7):920-30. PubMed ID: 24676715
[TBL] [Abstract][Full Text] [Related]
40. The polypill approach - An innovative strategy to improve cardiovascular health in Europe.
Fuster V; Gambús F; Patriciello A; Hamrin M; Grobbee DE
BMC Pharmacol Toxicol; 2017 Feb; 18(1):10. PubMed ID: 28166827
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
